SCHEMBL2018732

SCHEMBL2018732

COC(=O)Cc1cn(C(=O)OC(C)(C)C)c2ccccc12

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.78
EPHX1 P07099 1/20 0.52
PDE10A Q9Y233 1/20 0.49
HTR6 P50406 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ADAM17 P78536 1/20 0.46
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ACHE P22303 1/20 0.43
PIM1 P11309 1/20 0.43
MARK3 P27448 1/20 0.43
MAP4K2 Q12851 1/20 0.43
CAMK2B Q13554 1/20 0.43
PIM3 Q86V86 1/20 0.43
PIM2 Q9P1W9 1/20 0.43
AKR1C3 P42330 1/20 0.42
EGFR P00533 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29651147 1.00 L3MBTL1 (0.78) L3MBTL1EPHX1PDE10AHTR6MEN1
SCHEMBL15747688 0.88 L3MBTL1 (0.60) L3MBTL1MEN1KMT2AMAPTHPGD
SCHEMBL13343761 0.88 L3MBTL1 (0.67) L3MBTL1EPHX1PDE10AHTR6MEN1
SCHEMBL3169068 0.88 L3MBTL1 (0.64) L3MBTL1EPHX1PDE10AHTR6MEN1
SCHEMBL5740608 0.88 L3MBTL1 (1.00) L3MBTL1EPHX1PDE10AHTR6MEN1
SCHEMBL12572728 0.87 L3MBTL1 (0.73) L3MBTL1EPHX1PDE10AHTR6MEN1
SCHEMBL2882457 0.87 L3MBTL1 (0.73) L3MBTL1EPHX1PDE10AHTR6MEN1
SCHEMBL30777140 0.86 L3MBTL1 (0.72) L3MBTL1EPHX1PDE10AHTR6MEN1
SCHEMBL10088115 0.85 L3MBTL1 (0.74) L3MBTL1EPHX1PDE10AHTR6MEN1
SCHEMBL1520892 0.85 L3MBTL1 (0.70) L3MBTL1EPHX1PDE10AHTR6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612424-B2 HPK1 inhibitors and uses thereof REGOR PHARMACEUTICALS, INC. (US) 2026-04-28 US disclosed
WO-2023134608-A1 FUSED RING COMPOUNDS SERVING AS HPK1 INHIBITORS 微境生物医药科技(上海)有限公司 2023-07-20 WO disclosed
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF REGOR PHARMACEUTICALS, INC. 2022-12-08 US disclosed
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF REGOR PHARMACEUTICALS, INC. 2022-12-08 US disclosed
WO-2021000935-A1 HPK1 INHIBITORS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2021-01-07 WO disclosed
WO-2017098733-A1 INDOLE ACETIC ACID DERIVATIVE 株式会社 東北テクノアーチ 2017-06-15 WO disclosed
WO-2017098731-A1 4-PHENYL-4-OXOBUTANOIC ACID DERIVATIVE 株式会社 東北テクノアーチ 2017-06-15 WO disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
WO-2011082266-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20100113466-A1 OXAZOLE-PYRIDAZINE-OXAZOLE ALPHA-HELIX MIMETIC THE SCRIPPS RESEARCH INSTITUTE 2010-05-06 US disclosed
WO-2010042758-A2 OXAZOLE-PYRIDAZINE-OXAZOLE ALPHA-HELIX MIMETIC THE SCRIPPS RESEARCH INSTITUTE (US) 2010-04-15 WO disclosed
US-20100022549-A1 ALPHA-HELIX MIMETIC WITH FUNCTIONALIZED PYRIDAZINE THE SCRIPPS RESEARCH INSTITUTE (US) 2010-01-28 US disclosed
WO-2010011864-A2 ALPHA-HELIX MIMETIC WITH FUNCTIONALIZED PYRIDAZINE THE SCRIPPS RESEARCH INSTITUTE (US) 2010-01-28 WO disclosed
US-20100022549-A1 ALPHA-HELIX MIMETIC WITH FUNCTIONALIZED PYRIDAZINE THE SCRIPPS RESEARCH INSTITUTE (US) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612424-B2 HPK1 inhibitors and uses thereof NEK11, NEK1, CSNK1A1 L3MBTL1 2092/4885EPHX1 2462/4885PDE10A 2850/4885
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF HIPK1, SIK1, PGK1 L3MBTL1 2199/4885EPHX1 2811/4885PDE10A 3003/4885
US-20100113466-A1 OXAZOLE-PYRIDAZINE-OXAZOLE ALPHA-HELIX MIMETIC OXA1L, H1-4, H1-5 L3MBTL1 1151/4885EPHX1 1621/4885PDE10A 4131/4885
US-20100022549-A1 ALPHA-HELIX MIMETIC WITH FUNCTIONALIZED PYRIDAZINE H1-4, H1-5, H1-3 L3MBTL1 1812/4885EPHX1 2302/4885PDE10A 3959/4885
US-20110160237-A1 Substituted Heterocyclic Compounds MKI67, CCNC, NQO1 L3MBTL1 4509/4885EPHX1 522/4885PDE10A 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.